LaFayette, NY (PRWEB) July 07, 2015
Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today that it has received $79,775 in new grant funding from Methuselah Foundation, a 501(c)3 non-profit that funds regenerative medicine R&D.
This news comes in response to pilot studies completed at Ichor during winter 2014-2015 where c60oo administration doubled median lifespan in a mouse model of acute myeloid leukemia. Acute myeloid leukemia is a lethal blood cancer with only a 24% five-year survival rate.
“Like any preliminary study, we must be cautious not to jump too quickly at promising data,” noted Ichor CEO Kelsey Moody. “This new grant will enable us to confirm our previous findings, and also begin to study biodistribution and pharmacokinetics within our model.”
Such studies will include the distribution of c60oo into different organ tissues and half-life in blood plasma, in addition to assessing survival outcomes. Moody noted that success with this project could enable Ichor scientists to begin testing c60oo as an adjuvant for, and head-to-head with, traditional chemotherapy in mice in less than a year.
“Methuselah Foundation remains a prominent sponsor of research on aging and age-related disease,” stated Moody. “They have supported this project since our initial crowd-funding campaign through Longecity.org, and we look forward to continuing to build upon our strong relationship in the future.”
About Ichor Therapeutics, Inc.: Ichor Therapeutics, Inc. (http://www.ichortherapeutics.com) is a privately held pre-clinical biotechnology company in LaFayette, NY. Founded in 2013 by then SUNY Upstate Medical University student Kelsey Moody, the company has raised over $1 million to support research in eye disease and oncology.